Nanologica AB (publ) (STO:NICA)
0.3590
-0.0070 (-1.91%)
Sep 2, 2026, 5:29 PM CET
Nanologica AB Revenue
Nanologica AB had revenue of 25.38M SEK in the quarter ending June 30, 2026, with 1,079.32% growth. This brings the company's revenue in the last twelve months to 53.45M, up 6,071.82% year-over-year. In the year 2025, Nanologica AB had annual revenue of 21.05M, down -36.85%.
Revenue (ttm)
53.45M
Revenue Growth
+6,071.82%
P/S Ratio
0.88
Revenue / Employee
1.89M
Employees
72
Market Cap
120.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.05M | -12.28M | -36.85% |
| Dec 31, 2024 | 33.33M | 26.09M | 360.03% |
| Dec 31, 2023 | 7.25M | 2.43M | 50.46% |
| Dec 31, 2022 | 4.82M | -8.69M | -64.35% |
| Dec 31, 2021 | 13.51M | -6.52M | -32.55% |
| Dec 31, 2020 | 20.03M | 5.81M | 40.87% |
| Dec 31, 2019 | 14.22M | 9.82M | 223.23% |
| Dec 31, 2018 | 4.40M | -4.22M | -48.93% |
| Dec 31, 2017 | 8.61M | 2.99M | 53.30% |
| Dec 31, 2016 | 5.62M | -3.80M | -40.37% |
| Dec 31, 2015 | 9.42M | 2.78M | 41.78% |
| Dec 31, 2014 | 6.65M | -2.84M | -29.90% |
| Dec 31, 2013 | 9.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xbrane Biopharma AB | 83.30M |
| Biovica International AB | 13.49M |
| NextCell Pharma AB | 10.78M |
| Abera Bioscience AB | 9.10M |
| Elicera Therapeutics AB | 7.79M |
| Xintela AB | 3.03M |
| Simris Group AB (PUBL) | 1.39M |
| Diamyd Medical AB | 432.00K |
Nanologica AB News
- 2 days ago - Nanologica AB Quarterly report: Q2 2026 - Filings
- 3 months ago - Nanologica AB Quarterly report: Q1 2026 - Filings
- 6 months ago - Nanologica AB Quarterly report: Q4 2025 - Filings
- 6 months ago - Nanologica AB Annual report: Q4 2025 - Filings
- 10 months ago - Nanologica AB Quarterly report: Q3 2025 - Filings